GLP-1 or SGLT2 drugs and pneumonia recovery in diabetes
Part of Hormones & metabolism, Infections, Lungs & breathing clinical trials.
This trial looks at whether taking certain diabetes medications (GLP-1 agonists or SGLT2 inhibitors) before being hospitalized for pneumonia can improve early recovery in adults with type 2 diabetes. It compares these drugs to standard diabetes treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have type 2 diabetes.
- You were hospitalized for pneumonia during the study period.
- You took a GLP-1 receptor agonist, SGLT2 inhibitor, or standard diabetes medicine in the year before going to the hospital.
- You did not take a GLP-1 or SGLT2 drug in the 6 months before starting your first qualifying prescription.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether breathing exercises with essential oils can help people with type 2 diabetes recover from a lung infection while in the hospital. It aims to see if this approach makes breathing easier and speeds up recovery.
This trial tests different treatments for serious lung infections in people who are already in the hospital. It may help doctors learn which treatment works best for recovery and survival when pneumonia-like illness is suspected.
This study looks at blood markers (special proteins) in patients who have had both a heart attack and pneumonia, to see how vaccination affects recovery. The goal is to understand whether flu and pneumonia vaccines are safe and helpful for people recovering from these two serious conditions together.
This study tests a pneumococcal vaccine designed for 20 types of bacteria in older adults who are hospitalized with suspected community-acquired pneumonia. It aims to see how the vaccine works in real-world care and whether it affects how pneumonia happens or progresses.
This is a retrospective study (looking back at past patient records) of people hospitalized with pneumonia to understand how the disease progresses and what factors affect recovery. Researchers will examine medical records of pneumonia patients admitted within 72 hours of symptom onset to identify patterns in who recovers well and who develops serious complications.
This study looks at whether certain diabetes medicines, called SGLT2 inhibitors and GLP-1 receptor agonists, can help protect the heart in people with type 2 diabetes. It may help you understand if these treatments are a good option for your heart health.
Hear when a new Pneumonia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.